About Keratin, type I cytoskeletal 24
Keratin, type I cytoskeletal 24 (KRT24) is a protein
from Homo sapiens identified by UniProt accession
Q2M2I5, 525 residues long.
MolForge cross-references it against 0 known binders and
42 disease associations.
Target properties
| Protein name | Keratin, type I cytoskeletal 24 |
| UniProt accession | Q2M2I5 |
| Gene | KRT24 |
| Organism | Homo sapiens |
| Length | 525 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (42)
Diseases linked to this target (Open Targets).
- head and neck squamous cell carcinoma · score 0.19
- glioblastoma multiforme · score 0.19
- prostate adenocarcinoma · score 0.18
- ovarian cancer · score 0.18
- clear cell renal carcinoma · score 0.18
- breast adenocarcinoma · score 0.18
- serum albumin measurement · score 0.17
- seasonal allergic rhinitis · score 0.14
- neuroblastoma · score 0.13
- asthma · score 0.12
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q2M2I5-F1 | alphafold | PREDICTED | 69.86 | — |
Amino-acid sequence (525 residues)
MSCSSRASSS RAGGSSSARV SAGGSSFSSG SRCGLGGSSA QGFRGGASSC SLSGGSSGAF GGSFGGGFGS CSVGGGFGGA SGSGTGFGGG SSFGGVSGFG RGSGFCGSSR FSSGATGGFY SYGGGMGGGV GDGGLFSGGE KQTMQNLNDR LANYLDKVRA LEEANTDLEN KIKEWYDKYG PGSGDGGSGR DYSKYYSIIE DLRNQIIAAT VENAGIILHI DNARLAADDF RLKYENELCL RQSVEADING LRKVLDDLTM TRSDLEMQIE SFTEELAYLR KNHEEEMKNM QGSSGGEVTV EMNAAPGTDL TKLLNDMRAQ YEELAEQNRR EAEERFNKQS ASLQAQISTD AGAATSAKNE ITELKRTLQA LEIELQSQLA MKSSLEGTLA DTEAGYVAQL SEIQTQISAL EEEICQIWGE TKCQNAEYKQ LLDIKTRLEV EIETYRRLLD GEGGGSSFAE FGGRNSGSVN MGSRDLVSGD SRSGSCSGQG RDSSKTRVTK TIVEELVDGK VVSSQVSSIS EVKVK
Explore Keratin, type I cytoskeletal 24 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets